These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1508435)

  • 21. Methods for deriving pesticide aquatic life criteria.
    TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
    Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developmental neurotoxicity guideline study: issues with methodology, evaluation and regulation.
    Tsuji R; Crofton KM
    Congenit Anom (Kyoto); 2012 Sep; 52(3):122-8. PubMed ID: 22925212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Databases applicable to quantitative hazard/risk assessment--towards a predictive systems toxicology.
    Waters M; Jackson M
    Toxicol Appl Pharmacol; 2008 Nov; 233(1):34-44. PubMed ID: 18675838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testing methods for developmental neurotoxicity of environmental chemicals.
    Claudio L; Kwa WC; Russell AL; Wallinga D
    Toxicol Appl Pharmacol; 2000 Apr; 164(1):1-14. PubMed ID: 10739739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-based exposure measurements in EPA region 5: a phase I field study in support of the National Human Exposure Assessment Survey.
    Pellizzari E; Lioy P; Quackenboss J; Whitmore R; Clayton A; Freeman N; Waldman J; Thomas K; Rodes C; Wilcosky T
    J Expo Anal Environ Epidemiol; 1995; 5(3):327-58. PubMed ID: 8814775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. U.S. Environmental Protection Agency procedures and policies to estimate risk of injury to the male reproductive system.
    Francis EZ
    Prog Clin Biol Res; 1989; 302():3-16; discussion 17-20. PubMed ID: 2755956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of the toxicity of chemical mixtures: Theory, policy, and regulatory practice.
    McCarty LS; Borgert CJ
    Regul Toxicol Pharmacol; 2006 Jul; 45(2):119-43. PubMed ID: 16701933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration Proposed Guidelines for Neurotoxicological Testing of Food Chemicals.
    Sobotka TJ; Ekelman KB; Slikker W; Raffaele K; Hattan DG
    Neurotoxicology; 1996; 17(3-4):825-36. PubMed ID: 9086506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update of potency factors for asbestos-related lung cancer and mesothelioma.
    Berman DW; Crump KS
    Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Default assumptions in carcinogen risk assessment used by regulatory agencies.
    Moolenaar RJ
    Regul Toxicol Pharmacol; 1994 Dec; 20(3 Pt 2):S135-41. PubMed ID: 7724845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
    Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A proposed methodology for selecting a trichloroethylene inhalation unit risk value for use in risk assessment.
    Lewandowski TA; Rhomberg LR
    Regul Toxicol Pharmacol; 2005 Feb; 41(1):39-54. PubMed ID: 15649826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoption of new guidelines and data requirements for more extensive neurotoxicity testing under FIFRA.
    Sette WF
    Toxicol Ind Health; 1989 Mar; 5(2):181-94. PubMed ID: 2728014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juvenile toxicity testing protocols for chemicals.
    Piersma AH; Tonk EC; Makris SL; Crofton KM; Dietert RR; van Loveren H
    Reprod Toxicol; 2012 Nov; 34(3):482-6. PubMed ID: 22564981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the U.S. Environmental Protection Agency methods for identification of hazards to developing organisms, Part II: The developmental toxicity testing guideline.
    Claudio L; Bearer CF; Wallinga D
    Am J Ind Med; 1999 Jun; 35(6):554-63. PubMed ID: 10332508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program.
    Borgert CJ; Mihaich EM; Ortego LS; Bentley KS; Holmes CM; Levine SL; Becker RA
    Regul Toxicol Pharmacol; 2011 Nov; 61(2):185-91. PubMed ID: 21803110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EPA's neurotoxicity risk assessment guidelines.
    Boyes WK; Dourson ML; Patterson J; Tilson HA; Sette WF; MacPhail RC; Li AA; O'Donoghue JL
    Fundam Appl Toxicol; 1997 Dec; 40(2):175-84. PubMed ID: 9441713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity: summary and implications.
    Francis EZ; Kimmel CA; Rees DC
    Neurotoxicol Teratol; 1990; 12(3):285-92. PubMed ID: 2196427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.